Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Mounjaro was launched in mid-2022, while Zepbound was launched in November 2023. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly, as they are ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

We recently compiled a list of the Jim Cramer’s Latest Game Plan: 20 Stocks to Watch. In this article, we are going to take a ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

We’re living in a world full of foods that trigger constant hunger, cravings and thoughts about eating. Is it even possible ...

Researchers looking at the sweltering European summer of 2022 estimated that more than half of the heat-linked deaths ...

Get the latest updates on Amgen's upcoming Q3 earnings results, including insights from analysts on key products and trial ...

Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...